Acceder Registro /

Mª Dolores García Malo

Buscador

Puiggros A, Ramos-Campoy S, Kamaso J, de la Rosa M, Salido M, Melero C, Rodríguez-Rivera M, Bougeon S, Collado R, Gimeno E, García-Serra R, Alonso S, Moro-García MA, García-Malo MD, Calvo X, Arenillas L, Ferrer A, Mantere T, Hoischen A, Schoumans J, Espinet B. Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL). Cancers (Basel). 2022 Jul 11;14(14). pii: 3376. doi: 10.3390/cancers14143376. PubMed PMID: 35884436; PubMed Central PMCID: PMC9317182.
AÑO: 2022; IF: 6.575
Carrillo-Tornel S, Chen-Liang TH, Zurdo M, Puiggros A, Gomez-Llonin A, Garcia-Malo MD, Cuenca-Zamora EJ, Ortuno FJ, Lopez AMH, Espinet B, Jerez A. NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition. Br J Haematol. 2022 Dec 27. doi: 10.1111/bjh.18609. Online ahead of print. PubMed PMID: 36573331.
AÑO: 2022; IF: 6.5
Bravo-Pérez C, Sola M, Teruel-Montoya R, García-Malo MD, Ortuño FJ, Vicente V, de Arriba F, Jerez A. Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. Cancers (Basel). 2021 Aug 27;13(17). pii: 4332. doi: 10.3390/cancers13174332. Review. PubMed PMID: 34503142; PubMed Central PMCID: PMC8430644.
AÑO: 2021; IF: 6.575
Bravo-Perez C, Fernández-Caballero M, Soler-Espejo E, Garcia-Torralba E, Sorigue M, García-Malo MD, Jerez A, Vicente V, Roldán V, de Arriba F. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma. J Thromb Thrombolysis. 2021 Oct;52(3):848-853. doi: 10.1007/s11239-021-02407-5. Epub 2021 Mar 1. PubMed PMID: 33649980.
AÑO: 2021; IF: 5.221
Abrisqueta P, Loscertales J, Terol MJ, Ramírez Payer Á, Ortiz M, Pérez I, Cuellar-García C, Fernández de la Mata M, Rodríguez A, Lario A, Delgado J, Godoy A, Arguiñano Pérez JM, Berruezo MJ, Oliveira A, Hernández-Rivas JÁ, García Malo MD, Medina Á, García Martin P, Osorio S, Baltasar P, Fernández-Zarzoso M, Marco F, Vidal Manceñido MJ, Smucler Simonovich A, López Rubio M, Jarque I, Suarez A, Fernández Álvarez R, Lancharro Anchel A, Ríos E, Losada Castillo MDC, Pérez Persona E, García Muñoz R, Ramos R, Yáñez L, Bello JL, Loriente C, Acha D, Villanueva M. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). Clin Lymphoma Myeloma Leuk. 2021 Dec;21(12):e985-e999. doi: 10.1016/j.clml.2021.07.022. Epub 2021 Aug 3. PubMed PMID: 34511320.
AÑO: 2021; IF: 2.822

Instituto de Investigación Sanitaria Acreditado

ISCII

Fondo Social Europeo "El FSE Invierte en tu futuro"

Fondo Social Europeo

Sello de Calidad Europeo "HR Excellence in Research"

HRS4R